Viveve Medical Inc (NASDAQ:VIVE) saw a significant increase in short interest in the month of November. As of November 29th, there was short interest totalling 353,600 shares, an increase of 176.5% from the November 14th total of 127,900 shares. Currently, 24.6% of the shares of the stock are sold short. Based on an average daily volume of 1,276,500 shares, the short-interest ratio is presently 0.3 days.
Shares of VIVE opened at $0.84 on Friday. Viveve Medical has a 12 month low of $0.79 and a 12 month high of $148.00. The stock’s 50 day moving average is $2.86 and its two-hundred day moving average is $1.68. The firm has a market cap of $1.21 million, a P/E ratio of -0.01 and a beta of -0.06.
Viveve Medical (NASDAQ:VIVE) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($13.51) EPS for the quarter, beating the consensus estimate of ($16.00) by $2.49. Viveve Medical had a negative return on equity of 2,979.48% and a negative net margin of 429.71%. The company had revenue of $1.05 million for the quarter. On average, analysts anticipate that Viveve Medical will post -15.17 earnings per share for the current fiscal year.
In other Viveve Medical news, major shareholder Goldman Sachs Group Inc sold 24,817 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $5.52, for a total value of $136,989.84. 5.20% of the stock is currently owned by company insiders.
An institutional investor recently bought a new position in Viveve Medical stock. FNY Investment Advisers LLC purchased a new position in Viveve Medical Inc (NASDAQ:VIVE) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,136 shares of the company’s stock, valued at approximately $71,000. FNY Investment Advisers LLC owned about 1.10% of Viveve Medical at the end of the most recent reporting period. 32.96% of the stock is currently owned by institutional investors and hedge funds.
VIVE has been the topic of several research analyst reports. LADENBURG THALM/SH SH raised Viveve Medical from a “neutral” rating to a “buy” rating in a report on Tuesday, December 3rd. ValuEngine lowered Viveve Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 23rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $2.05.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.
Further Reading: What is an economic bubble?
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.